Targeting CXCR4-dependent immunosuppressive Ly6C low monocytes improves antiangiogenic therapy in colorectal cancer
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Significance: The survival benefit of antiangiogenic therapies for cancer patients has been limited, potentially due to intrinsic/acquired resistance. Deciphering and targeting resistance mechanisms are critical to improving treatment outcome, especially in cancers where antiangiogenic therapies are standard of care, such as colorectal cancer (CRC). Consistent with our clinical findings, we found up-regulation of CXCL12/CXCR4 in orthotopic CRC models and conditional Apc mutant spontaneous rectal tumors after anti-VEGFR2 treatment. CXCR4 signaling recruited immunosuppressive innate immune cells such as Ly6C low monocytes and Ly6G + neutrophils to the CRCs, conferring resistance to VEGFR2 blockade. Furthermore, we successfully targeted these pathways genetically and pharmacologically, including with an FDA-approved agent Plerixafor (AMD3100), which significantly enhanced treatment response. These strategies have the potential for rapid clinical translation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“preclinical evidence indicates that high-dose and/or long-term antiangiogenic therapy causes massive vessel pruning and increases immunosuppression in tumour models37–40”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“suggesting that an optimum level of VEGF and ANG2 blockade will be needed to alleviate immunosuppression in the TME”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“High doses of anti-VEGF agents can also lead to increased deposition of extracellular matrix that, together with hypoxia, can promote the infiltration of immunosuppressive and/or pro-tumour immune cells, such as monocytic and granulocytic MDSCs37–39”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In mouse models of CRC, high-dose anti-VEGF treatment can also result in the recruitment of immunosuppressive, nonclassical, lymphocyte antigen 6C (Ly6C)low monocytes that also confer resistance to anti-VEGF therapy, thus setting up a vicious cycle38,39”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [38]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“emerging data suggest that immunosuppression, in turn, contributes to resistance to antiangiogenesis treatments37–39,41”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Blood Monocytes Consist of Two Principal Subsets with Distinct Migratory Properties
Geissmann, F., Jung, S., & Littman, D. R. (2003) · Immunity · doi:10.1016/s1074-7613(03)00174-2 · Cited by 3,391
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733
Jung, S., Aliberti, J., Graemmel, P., Sunshine, M. J., Kreutzberg, G. W., Sher, A., & Littman, D. R. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.11.4106-4114.2000 · Cited by 2,632 · cited 1×
“We specifically inhibited the infiltration of Ly6C monocytes by using Cx3cr1 mice as described previously (9, 29, 30).”
MethodNahrendorf, M., Swirski, F. K., Aikawa, E., Stangenberg, L., Wurdinger, T., Figueiredo, J.-L., Libby, P., Weissleder, R., & Pittet, M. J. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070885 · Cited by 2,300
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008
Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,966
Self-citation
Cited by
Inflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 2,792
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Self-citationMacrophage-Based Approaches for Cancer Immunotherapy
Anderson, N. R., Minutolo, N. G., Gill, S., & Klichinsky, M. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2990 · Cited by 698
Lee, W. S., Yang, H., Chon, H. J., & Kim, C. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00500-y · Cited by 688
Maalej, K. M., Merhi, M., Inchakalody, V. P., Mestiri, S., Alam, M., Maccalli, C., Cherif, H., Uddin, S., Steinhoff, M., Marincola, F. M., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01723-z · Cited by 618
Metadata
- Authors
- Jung, K., Heishi, T., Incio, J., Huang, Y., Beech, E. Y., Pinter, M., Ho, W. W., Kawaguchi, K., Rahbari, N. N., Chung, E., Kim, J. K., Clark, J. W., Willett, C. G., Yun, S. H., Luster, A. D., Padera, T. P., Jain, R. K., & Fukumura, D.
- Affiliations
- Harvard University (US)
- Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Harvard Medical School and Massachusetts General Hospital, Boston, MA 02114;
- Duke Medical Center (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2017-09-12
- Volume
- 114
- Issue
- 39
- Pages
- 10455-10460
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC5625928
- OpenAlex
- W2754366826
- Cited by
- 138
- References
- 57
- Citations by year
- 2026: 10 · 2025: 12 · 2024: 15 · 2023: 17 · 2022: 18 · 2021: 23 · 2020: 19 · 2019: 15 · 2018: 9
- FWCI
- 4.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- HHS | NIH | National Cancer Institute (P01-CA080124, R01-CA126642, R35-CA197743, CA096915)
- HHS | National Institutes of Health (DP2 OD008780, R00 CA137167)
- DOD | U.S. Army (W81XWH-10-1-0016)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- colorectal cancer, anti-angiogenic therapy, CXCR4, CXCL12, neutrophils, immunosuppression, treatment resistance, plerixafor, tumor microenvironment, innate immune cells
- MeSH terms
- Bevacizumab, Cyclams, Ramucirumab, Animals, Antibodies, Monoclonal, Antigens, Ly, Benzylamines, Heterocyclic Compounds, Mice, Inbred C57BL, Monocytes, Neutrophils, Tumor Cells, Cultured, Colorectal Neoplasms, Mice, Knockout, Receptors, CXCR4, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor Receptor-2, Vascular Endothelial Growth Factor A, Cell Proliferation, Mice, Chemokine CXCL12, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting CXCR4-dependent immunosuppressive Ly6C low monocytes improves antiangiogenic therapy in colorectal cancer. https://app.cochat.ai/papers/10.1073/pnas.1710754114
- The paper
- Jung, K., Heishi, T., Incio, J., Huang, Y., Beech, E. Y., Pinter, M., Ho, W. W., Kawaguchi, K., Rahbari, N. N., Chung, E., Kim, J. K., Clark, J. W., Willett, C. G., Yun, S. H., Luster, A. D., Padera, T. P., Jain, R. K., & Fukumura, D. (2017). Targeting CXCR4-dependent immunosuppressive Ly6C low monocytes improves antiangiogenic therapy in colorectal cancer. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1710754114
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.